Protalix BioTherapeutics, Inc. (PLX) Earnings History
Annual and quarterly earnings data from 1996 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 54.5% | 7.3% | 5.5% |
| 2023 | 64.9% | 16.0% | 12.7% |
| 2022 | 58.9% | -27.3% | -31.3% |
| 2021 | 57.4% | -53.4% | -71.9% |
| 2020 | 82.7% | 4.3% | -10.4% |
Download Data
Export PLX earnings history in CSV or JSON format
Free sign-in required to download data
Protalix BioTherapeutics, Inc. (PLX) Earnings Overview
As of February 28, 2026, Protalix BioTherapeutics, Inc. (PLX) reported trailing twelve-month net income of $5M, reflecting -0.6% year-over-year growth. The company earned $0.07 per diluted share over the past four quarters, with a net profit margin of 0.1%.
Looking at the long-term picture, PLX's historical earnings data spans multiple years. The company achieved its highest annual net income of $58M in fiscal 2015.
Protalix BioTherapeutics, Inc. maintains positive profitability with a gross margin of 0.5%, operating margin of 0.1%, and net margin of 0.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including AGIO (-$401M net income, -7.6% margin), VRTX ($3.68B net income, 0.3% margin), ASND (-$228M net income, -0.3% margin), PLX has outperformed on profitability metrics. Compare PLX vs AGIO →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
29 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $3M | -64.7% | $4M | $0.04 | 5.5% | 7.3% |
| 2023 | $8M | +155.7% | $10M | $0.10 | 12.7% | 16.0% |
| 2022 | -$15M | +45.9% | -$13M | $-0.31 | -31.3% | -27.3% |
| 2021 | -$28M | -322.8% | -$20M | $-0.62 | -71.9% | -53.4% |
| 2020 | -$7M | +64.3% | $3M | $-0.22 | -10.4% | 4.3% |
| 2019 | -$18M | +30.9% | -$11M | $-1.23 | -33.4% | -19.6% |
| 2018 | -$26M | +68.3% | -$19M | $-1.80 | -77.3% | -56.4% |
| 2017 | -$83M | -184.1% | -$35M | $-6.50 | -395.9% | -163.8% |
| 2016 | -$29M | -150.6% | -$33M | $-0.29 | -319.2% | -360.5% |
| 2015 | $58M | +293.8% | -$24M | $0.61 | 1329.9% | -542.4% |
See PLX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PLX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PLX vs AGIO
See how PLX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PLX growing earnings?
PLX EPS of $0.07 reflects slowing growth at -0.6%, below the 5-year CAGR of N/A. TTM net income is $5M. Expansion rate has moderated.
What are PLX's profit margins?
Protalix BioTherapeutics, Inc. net margin is +0.1%, with operating margin at +0.1%. Below-average margins reflect competitive or cost pressures.
How consistent are PLX's earnings?
PLX earnings data spans 1996-2024. The current earnings trend is -0.6% YoY. Historical data enables comparison across business cycles.